A TLR7 agonist strengthens T and NK cell function during BRAF‐targeted therapy in a preclinical melanoma model

Therapeutic success of targeted therapy with BRAF inhibitors (BRAFi) for melanoma is limited by resistance development. Observations from preclinical mouse models and recent insights into the immunological effects caused by BRAFi give promise for future development of combination therapy for human m...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Cancer
Main Authors: Bellmann, Lydia, Cappellano, Giuseppe, Schachtl‐Riess, Johanna F., Prokopi, Anastasia, Seretis, Athanasios, Ortner, Daniela, Tripp, Christoph H., Brinckerhoff, Constance E., Mullins, David W., Stoitzner, Patrizia
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2019
Assuntos:
Tumor Immunology and Microenvironment
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7003881/
https://ncbi.nlm.nih.gov/pubmed/31702822
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.32777
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados